Skip to main content

CLINICAL TRIAL article

Front. Cardiovasc. Med.
Sec. Clinical and Translational Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1506917

Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial

Provisionally accepted
Li-Qin Meng Li-Qin Meng 1Qing-Min Li Qing-Min Li 2Yu-Chao Feng Yu-Chao Feng 3Ding-Jian Li Ding-Jian Li 4Peiying Huang Peiying Huang 3Guang-Long Wu Guang-Long Wu 4Bo-Wen Ao Bo-Wen Ao 4Guo-Chao Wu Guo-Chao Wu 5Guo-Xiong Zhang Guo-Xiong Zhang 3Bojun Chen Bojun Chen 1,3*
  • 1 Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China
  • 2 The First People's Hospital of Chenzhou, Chenzhou, Hunan Province, China
  • 3 Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China
  • 4 People's Hospital of Yangjiang, Yangjiang, Guangdong Province, China
  • 5 Guangdong Medical University, Zhanjiang, Guangdong, China

The final, formatted version of the article will be published soon.

    Background: The efficacy and mechanism of Fufang Danshen dripping pills (FFDS) in the secondary prevention of stable coronary heart disease (SCHD) is currently undetermined. This study aims to investigate the efficacy and preliminary mechanism by which FFDS may impact the progression of SCHD. Methods: Based on randomization, we administered oral FFDS to 30 patients with SCHD in addition to conventional treatment for 30 days. After treatment, three-months major adverse cardiovascular events (MACE) were assessed as the primary outcome. Additionally, we evaluated the patients' Seattle Angina Questionnaire score, blood pressure, circulating levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, C-reactive protein, platelets, alanine aminotransferase, aspartate aminotransferase, serum creatinine, and fasting blood glucose as the secondary outcomes. Furthermore, we utilized mass spectrometry analysis, network pharmacology, and circulating lipidomics analysis to predict the potential mechanisms of FFDS in the treatment of SCHD. Results: Following treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P=0.013) and a reduction in the frequency of angina episodes (P=0.021). We conducted mass spectrometry analysis on FFDS and identified 236 chemical components. Lipidomics further confirmed triglycerides as key lipids affected by FFDS. By integrating these findings with network pharmacology targets, we highlighted the potential roles of LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT in fat digestion, absorption, and metabolism pathways, suggesting their involvement in FFDS's treatment of SCHD by reducing triglyceridesSubsequent analyses highlighted the potential involvement of LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT in the mechanisms underlying fat digestion, absorption, and metabolism pathways, which are implicated in the treatment of SCHD by FFDS.In individuals with SCHD, the administration of FFDS has been shown to effectively reduce circulating triglyceride levels and decrease the frequency of angina episodes. This therapeutic effect is likely due to the active components of FFDS targeting key proteins: LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT.

    Keywords: Fufang Danshen dripping pills, Stable coronary heart disease, Triglycerides, Angina frequency, lipidomics

    Received: 23 Oct 2024; Accepted: 14 Jan 2025.

    Copyright: © 2025 Meng, Li, Feng, Li, Huang, Wu, Ao, Wu, Zhang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Bojun Chen, Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.